| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1039309444 |
| P356 | DOI | 10.1186/S12885-016-2961-2 |
| P932 | PMC publication ID | 5127037 |
| P698 | PubMed publication ID | 27894291 |
| P2093 | author name string | Adrianus Johannes Christiaan van den Brule | |
| Carola de Wild | |||
| Cindy Leeijen | |||
| Cornelis Johannes Jacobus Huijsmans | |||
| Hendrikus Lambertus Cornelius Maria Hazenberg | |||
| Jenneke van Beek | |||
| Johannes Cornelis van der Linden | |||
| Willemina Rosalia Rita Geurts-Giele | |||
| P2860 | cites work | A review of the clinical performance of the Aptima HPV assay | Q26776336 |
| The Measurement of Observer Agreement for Categorical Data | Q26778373 | ||
| Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test | Q30300975 | ||
| POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women | Q30917882 | ||
| A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial) | Q33545461 | ||
| HPV testing by cobas HPV test in a population from Catalonia | Q34618650 | ||
| Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay | Q34637954 | ||
| Clinical validation of the cobas 4800 HPV test for cervical screening purposes. | Q35530540 | ||
| Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? | Q35621096 | ||
| Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial | Q35870574 | ||
| Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above | Q35898888 | ||
| Comparing the performance of six human papillomavirus tests in a screening population | Q36663594 | ||
| Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older | Q37461977 | ||
| Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening | Q37496183 | ||
| Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials | Q38160099 | ||
| Hybrid Capture 2 and cobas human papillomavirus assays perform similarly on SurePath samples from women with abnormalities. | Q39909954 | ||
| A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes | Q40779391 | ||
| Validation of high-risk HPV tests for primary cervical screening | Q43762516 | ||
| Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). | Q51794674 | ||
| Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia | Q81190985 | ||
| Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial | Q81404025 | ||
| Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I | Q82317700 | ||
| Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial | Q82586477 | ||
| Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening | Q83603494 | ||
| Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets | Q84341096 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervix uterine cancer | Q160105 |
| workflow | Q627335 | ||
| P304 | page(s) | 922 | |
| P577 | publication date | 2016-11-28 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows | |
| P478 | volume | 16 |
| Q93144890 | Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA |
| Q60949243 | Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing |
| Q57035937 | Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities |
| Q92723164 | Development of the Patient's Experience and Attitude Colposcopy Eindhoven Questionnaire (PEACE-q) |
| Q33713068 | Epidemiological investigation of the relationship between common lower genital tract infections and high-risk human papillomavirus infections among women in Beijing, China. |
| Q54249443 | Human papillomavirus detection with genotyping by the cobas and Aptima assays: Significant differences in HPV 16 detection? |
| Q57791055 | Human papillomaviruses other than 16, 18 and 45 are the major high risk HPV genotypes amongst women with abnormal cervical smear cytology residing in Kuwait: Implications for future vaccination strategies |
| Q91910518 | Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study |
| Q91706741 | Population-based primary HPV mRNA cervical screening compared with cytology screening |
| Q52571725 | The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results. |
| Q92165420 | The impact of knowledge of HPV positivity on cytology triage in primary high-risk HPV screening |
Search more.